All In Biotech

Drug Trial Radar · NCT07903337

A Phase 1, Open-Label, Two-Stage, Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-1071 Under Fasted or Fed Conditions in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Sponsor type
Industry
Collaborators
Taipei Medical University Hospital
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 1, open-label, two-stage, sequential food effect study to evaluate the safety, tolerability, and PK of EI-1071 under fasted or fed conditions in HVs. Approximately 25 evaluable participants will be enrolled in this study, including 11 participants in Stage 1 and 14 participants in Stage 2. Stage 2 study may be conducted based on the results of Stage 1 study.

Conditions

  • Food Effect in Healthy Volunteers

Interventions

  • EI-1071Drug

    EI-1071 tablet, oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1 Area under the curve [AUC] from time 0 to the last quantifiable time [AUC0-t]Time frame: Day 1 to Day 4 of each single dose period
  2. Stage 1 AUC from time 0 to infinity [AUC0-∞], and maximum concentration [Cmax]Time frame: Day 1 to Day 4 of each single dose period
  3. Stage 1 Time to Cmax (Tmax)Time frame: Day 1 to Day 4 of each single dose period
  4. Stage 1 Half-life (t1/2)Time frame: Day 1 to Day 4 of each single dose period
  5. Stage 1 Apparent clearance (CL/F)Time frame: Day 1 to Day 4 of each single dose period
  6. Stage 1 Apparent volume of distribution (Vz/F)Time frame: Day 1 to Day 4 of each single dose period
  7. Stage 2 Incidence and severity of TEAEs and TESAEs,Time frame: From Day 1 to Day 21 (EOS visit)
  8. Stage 2 Physical examinationTime frame: Screening, Day -1, Day 21
  9. Stage 2 Vital signsTime frame: Screening, Day -1 to Day 21
  10. Stage 2 Laboratory testsTime frame: Screening, Day -1, Day 7, Day 14, Day 21
  11. Stage 2 12-lead ECGTime frame: Screening, Day 1, Day 14, Day 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taipei Medical University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.